{"id":"W2761943820","doi":"10.1093/annonc/mdx365.018","title":"Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Lapatinib; Internal medicine; Adverse effect; Immunohistochemistry; HER2/neu; Oncology; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074792,0.001438136,0.001714912,0.00052306,0.0004061003,0.0008219422,0.0008011383,0.0009164923,0.003478434],"category_scores_gemma":[0.0006409694,0.0006196662,0.0009824408,0.0003718291,0.0007347332,0.0008454556,0.0003279302,0.002952939,0.0007939769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001144428,"about_ca_system_score_gemma":0.001512043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001535087,"about_ca_topic_score_gemma":0.003540836,"domain_scores_codex":[0.9997775,0.00008152329,0.000009095782,0.00005170902,0.00002165505,0.00005859043],"domain_scores_gemma":[0.9997112,0.00003620658,0.0000472659,0.0000220982,0.00001936009,0.0001638271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6749901,0.1011546,0.00643485,0.0007183315,0.001517047,0.0003358476,0.0004891261,0.008737756,0.06419666,0.0006765314,0.006838146,0.1339112],"study_design_scores_gemma":[0.4793952,0.4934345,0.0114644,0.00002832512,0.0005736003,0.0003451849,0.0001081622,0.002902287,0.007077069,0.0004737951,0.004150358,0.00004706216],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946126,0.0007979292,0.0005010833,0.0002679685,0.00008915512,0.001699629,0.0006152865,0.00009562795,0.001320767],"genre_scores_gemma":[0.9888552,0.001199862,0.001647064,0.0005962973,0.00009479573,0.002102121,0.00179547,0.00004230569,0.003666817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003478434,"threshold_uncertainty_score":0.01163656,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1457377945457309,"score_gpt":0.4530770253092388,"score_spread":0.3073392307635079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}